Characterization of stage-specific tumor progression in TMPRSS2-ERG (fusion)-driven and non-fusion-driven prostate cancer in GEM models. [PDF]
Mol Carcinog, 2022 Raina K +13 more
europepmc +1 more source
Deletion of 3p13 is a late event linked to progression of TMPRSS2:ERG fusion prostate cancer
Cancer Management and Research, 2018 Martina Kluth,1,* Heinke Volta,1,* Mohammad Hussein,1 Billurvan Taskin,1 Sohall Frogh,1 Christina Möller-Koop,1 Franziska Büscheck,1 Frank Jacobsen,1 Maria Christina Tsourlakis,1 Andreas M Lübke,1 Andrea Hinsch,1 Till Clauditz,1 Markus ...
Kluth M +19 more
doaj
TMPRSS2-ERG fusion impacts anterior tumor location in men with prostate cancer. [PDF]
Prostate, 2021 Yamoah K +11 more
europepmc +1 more source
Sigma1 Targeting to Suppress Aberrant Androgen Receptor Signaling in Prostate Cancer. [PDF]
, 2017 Suppression of androgen receptor (AR) activity in prostate cancer by androgen depletion or direct AR antagonist treatment, although initially effective, leads to incurable castration-resistant prostate cancer (CRPC) via compensatory mechanisms including ...
Anderson, Kelsey N. +10 more
core +1 more source
Comprehensive analysis of oncogenic signatures and consequent repurposed drugs in TMPRSS2:ERG fusion-positive prostate cancer. [PDF]
Clin Transl Med, 2021 Yun JW +5 more
europepmc +1 more source
Covid-19 pathogenesis in prostatic cancer and TMPRSS2-ERG regulatory genetic pathway. [PDF]
Infect Genet Evol, 2021 Afshari A +4 more
europepmc +1 more source
Pathologie: Die TMPRSS2-ERG-Genfusion im Prostatakarzinom
Swiss Medical Forum ‒ Schweizerisches Medizin-Forum, 2011 KD Mertz, MA Rubin, G Cathomas
openaire +1 more source
Mapping Isoform Abundance and Interactome of the Endogenous TMPRSS2-ERG Fusion Protein by Orthogonal Immunoprecipitation-Mass Spectrometry Assays. [PDF]
Mol Cell Proteomics, 2021 Fu Z +5 more
europepmc +1 more source